WORCESTER, Mass., Oct. 9, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) announced today that Dr. Minzhen Xu, Vice President of Biology at Antigen Express, Inc., the Company's immunotherapy subsidiary, will make a presentation at a scientific symposium on the Company's strategy for converting cancer cells into potent tumor vaccine cells
Dr. Xu will present "Inhibition of MHC class II-associated Invariant Chain Generates Potent Tumor Cell Vaccine" at the 12th World Congress on Advances in Oncology to be held at the Creta Maris Hotel, Hersonissos, Crete, Greece, to be held from Oct. 11 through the 13th. The conference will focus on a variety of aspects of tumor biology and therapeutics. Dr. Xu will co-Chair and present in the Experimental Therapeutics/Vaccines section on Oct. 13th.
The talk by Dr. Xu will present pre-clinical studies that Antigen Express has performed in preparation for clinical trials in China. Robust anti-tumor immunity has been demonstrated in a variety of mouse tumor models as well as safety using the RNAi approached developed at Antigen Express. The trials in China will be performed in collaboration with Dr. Daopei Lu and the Beijing Daopei Hospital in Beijing, China. Dr. Lu is a world-renowned hematologist-oncologist who has conducted many clinical trials and has authored over 200 articles in peer-review journals.
The strategy being developed by Antigen Express is to force tumor cells to express tumor associated antigens in a way that that makes them more visible to the immune system. This is done by suppressing expression of the MHC class II-associated invariant chain in tumor cells using RNAi. MHC class II molecules are naturally expressed in many cells of the body including some types of cancer cells. The invariant chain prevents class II molecules from associating with antigenic peptides in the cytoplasm of cells (where tumor associated antigens are found) and presenting them for recognition by T helper cells. Antigen-specific stimulation of T helper cells is pivotal in allowing the immune system to recognize novel pathogenic agents. While a number of groups have demonstrated the efficacy of this strategy in pre-clinical models, Antigen Express has developed proprietary methods using RNAi that make this approach feasible in the clinic.
Antigen Express is focused on developing active immunotherapy products for serious diseases and unmet medical needs. Currently the company has an immunotherapeutic peptide in Phase II clinical trials for breast cancer and in Phase I trials for the potentially pandemic H5N1 avian influenza.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.